Detalhe da pesquisa
1.
A Phase I Open-Label Clinical Trial Evaluating the Therapeutic Vaccine hVEGF26-104/RFASE in Patients with Advanced Solid Malignancies.
Oncologist
; 26(2): e218-e229, 2021 02.
Artigo
Inglês
| MEDLINE | ID: mdl-33105058
2.
Targeted vaccination against the bevacizumab binding site on VEGF using 3D-structured peptides elicits efficient antitumor activity.
Proc Natl Acad Sci U S A
; 113(44): 12532-12537, 2016 11 01.
Artigo
Inglês
| MEDLINE | ID: mdl-27791128
3.
Vaccination approach to anti-angiogenic treatment of cancer.
Biochim Biophys Acta
; 1855(2): 155-71, 2015 Apr.
Artigo
Inglês
| MEDLINE | ID: mdl-25641676
4.
A functional bioassay to determine the activity of anti-VEGF antibody therapy in blood of patients with cancer.
Br J Cancer
; 115(8): 940-948, 2016 10 11.
Artigo
Inglês
| MEDLINE | ID: mdl-27575850
5.
Reply to Marchiò et al.: Antitumor immune regulation by angiostatic therapy.
Proc Natl Acad Sci U S A
; 114(16): E3166-E3167, 2017 04 18.
Artigo
Inglês
| MEDLINE | ID: mdl-28400520
6.
A safety and immunogenicity study of immunization with hVEGF26-104/RFASE in cynomolgus monkeys.
Vaccine
; 36(15): 2025-2032, 2018 04 05.
Artigo
Inglês
| MEDLINE | ID: mdl-29519591
7.
Phase I Study of Dalteparin in Combination With Sunitinib in Patients With Metastatic Clear Cell Renal Carcinoma.
Clin Genitourin Cancer
; 2017 Jul 14.
Artigo
Inglês
| MEDLINE | ID: mdl-28781191